Funds will support research into immunotherapy response rates and side effects
Immunotherapy can be a crucial tool for patients undergoing cancer treatment, vastly improving outcomes for many whose conditions would otherwise be fatal. Unfortunately a subset of these patients develop toxic autoimmune side effects to immune checkpoint inhibitor (ICI) treatment. If we could predict those individuals at risk of developing particular adverse events, interventions for such complications could be initiated in the timeliest fashion.
A new $1 million grant from the Mark Foundation for Cancer Research presented to The Jackson Laboratory will fund research to study why these side effects sometimes occur and use the power of genetics to predict better outcomes for patients. Read more
